CRISPR Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/E Ratio15.36
P/S Ratio90.0313.392656.646.3415045.33
P/B Ratio1.742.641.702.426.50
Price/Tangible Book1.742.641.702.426.50
Price/FCF12.68
Price/OCF10.76
Enterprise Value Ratios
EV/Revenue44.269.361211.763.8513213.93
EV/EBITDA9.01
EV/EBIT9.44
EV/FCF7.71
Profitability & Returns
Return on Equity (ROE)-0.19%-0.08%-0.30%0.19%-0.27%
Return on Assets (ROA)-0.13%-0.06%-0.17%0.10%-0.15%
Return on Invested Capital (ROIC)-1.37%-0.61%-2.45%2.65%-8.49%
Return on Capital Employed (ROCE)-0.22%-0.10%-0.32%0.14%-0.20%
Leverage & Solvency Ratios
Debt/Equity0.120.130.130.090.04
Debt/EBITDA0.53
Debt/FCF0.49
Liquidity Ratios
Current Ratio22.0717.5415.3020.1718.21
Quick Ratio22.0017.4715.0819.9218.05
Efficiency Ratios
Asset Turnover0.020.170.000.400.00
Yield & Distribution Ratios
Earnings Yield-0.11%-0.03%-0.20%0.07%-0.03%
FCF Yield-0.04%-0.05%-0.17%0.08%-0.02%
Buyback Yield-0.06%-0.02%0.03%-0.22%-0.16%